NEK2 and hepatocellular carcinoma: We found that when HepG2 and Hep3B HCC cells were treated with the anti-NEK2 3A3 mAb at final concentrations of 5 μg/mL and 25 μg/mL, respectively, cell proliferation was not affected (P > 0.05) (Fig. 4a, b).